| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 233.33% | HC Wainwright & Co. | $9 → $8 | Maintains | Buy |
| 08/28/2023 | 108.33% | JP Morgan | $15 → $5 | Downgrades | Overweight → Neutral |
| 05/05/2023 | 275% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 03/02/2023 | 275% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 01/24/2023 | 66.67% | Morgan Stanley | $7 → $4 | Maintains | Equal-Weight |
| 11/14/2022 | 191.67% | Morgan Stanley | $15 → $7 | Downgrades | Overweight → Equal-Weight |
| 11/11/2022 | — | Goldman Sachs | Downgrades | Buy → Neutral | |
| 10/17/2022 | 400% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 400% | Goldman Sachs | $21 → $12 | Maintains | Buy |
| 03/31/2022 | 775% | Goldman Sachs | $31 → $21 | Maintains | Buy |
| 01/06/2022 | 733.33% | Morgan Stanley | $25 → $20 | Maintains | Overweight |
| 07/12/2021 | 941.67% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 941.67% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 07/12/2021 | 816.67% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 1150% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
What is the target price for Lyell Immunopharma (LYEL)?
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by HC Wainwright & Co. on November 9, 2023. The analyst firm set a price target for $8.00 expecting LYEL to rise to within 12 months (a possible 233.33% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a maintained with a price target of $9.00 to $8.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.40, which is out of the analyst's predicted range.